Open AccessChemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer
Author(s) -
Edmond M. Kwan,
Arun Azad
Publication year - 2020
Publication title -
current opinion in urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.799
H-Index - 60
eISSN - 1473-6586
pISSN - 0963-0643
DOI - 10.1097/mou.0000000000000777
Subject(s) - enzalutamide , docetaxel , medicine , prostate cancer , oncology , chemotherapy , androgen receptor , androgen deprivation therapy , abiraterone acetate , cancer